Results 191 to 200 of about 280,420 (306)

MiR‐145‐5p Attenuates Doxorubicin‐Induced Heart Injury Through Targeting Cardiomyocyte Pyroptosis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Doxorubicin (DOX), a potent anthracycline chemotherapeutic, exhibits dose‐dependent cardiotoxicity that limits its clinical utility. Although miR‐145‐5p demonstrates cardioprotective properties in cardiovascular diseases, its role in DOX‐induced cardiomyopathy remains undefined.
Xing‐Tao Chen, Yong‐Hong Yu, Yan‐Hua Du, Lin Xu, Xiang‐Ping Meng   +4 more
wiley   +1 more source

RBMS1 orchestrates cardiac hypertrophy by facilitating CTTN splice-switching and sarcomere dynamics. [PDF]

EMBO Mol Med
Li L, Li T, Wang B, Feng J, Zhang N, Zhang J, Niu Z, Li W, Gao H, Wang Q, Liu Y, Chen Y, Zhang Y, Bian Y, Pan T, Sheng S, Li X, Liu J, Yang B, Liang H.   +19 more
europepmc   +1 more source

Sacubitril/Valsartan Ameliorates Inflammation and Oxidative Stress in Hypertensive Heart Disease by Upregulating CAMKK2 Protein and Modulating the AMPK/AKT/GSK‐3β Axis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Sacubitril/valsartan (Sac/Val) has emerged as an effective compound with myocardium‐protective functions in experimental and clinical trials for heart failure. This study investigated the function of Sac/Val in hypertensive heart disease (HHD) and explored the underlying mechanism.
Yan‐Jun Yang, Jiu‐Sheng Li
wiley   +1 more source

Breast cancer susceptibility gene 2 upregulation alleviated cardiac hypertrophy in angiotensin II-treated mice. [PDF]

Biochem Biophys Rep
Liu K, Gong XX, Li Y, Li MZ, Si C, Zhou L.   +5 more
europepmc   +1 more source

TET3‐Mediated m5C Modification of CCAT2 Accelerates Cardiac Microvascular Endothelial Cell Damage in Acute Coronary Syndrome

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Acute coronary syndrome (ACS) is a clinical syndrome involving myocardial ischemia. This study aimed to elucidate the mechanism of TET3 in ACS‐induced CMEC damage, thereby identifying a new target for ACS treatment. The expression of TET3 in ACS patients and healthy subjects was analyzed.
Jun‐Cheng Liu, Wen‐Juan Wang, Ting‐Ting Zhang, Qi‐Chong Yang, Haliminai Dilimulati, Song‐Tao An   +5 more
wiley   +1 more source

Mitophagy in Hypertensive Cardiac Hypertrophy: Mechanisms and Therapeutic Implications. [PDF]

J Clin Hypertens (Greenwich)
Li S, Li X.
europepmc   +1 more source

Alogliptin Reduces Oxidative Stress in Cardiomyocytes and Ameliorates Diabetic Cardiomyopathy via the AURKB/NLGN2 Signaling

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Diabetic cardiomyopathy (DCM) is a common complication of diabetes mellitus. This study investigated the effects of alogliptin on DCM and its underlying mechanisms. A DCM model was constructed and treated with alogliptin. Downstream targets of alogliptin were screened using bioinformatics analysis.
Li‐Jing Jiao, Jing Zhou, Jing Wang, Si‐Nan Zhao, Zhan‐Sheng Zhao, Qian Wang, Ya‐Nan Xie, Wei Jiao   +7 more
wiley   +1 more source

MicroRNA mediated regulation in early-onset cardiac hypertrophy: Insights from the hypertrophic heart rat model. [PDF]

PLoS One
Sadiq S, Charchar FJ, Sanigorski A, Crowley T, Bookun HR, McClure DN.   +5 more
europepmc   +1 more source

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

Med Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang, Ge Zhang, Tian‐Ding Liu, Tianshu Gu, Fengyi Yu, Pengyuan Xu, Wunan Mi, Xuanjiang Zhao, Qian Guo, Honglin Zheng, Taiqi Zhao, Qiang Li, Di Lu, Mingxuan Duan, Chaoyang Yu, Ruhao Wu, Shiqian Zhang, Haonan Zhang, Zeyu Wang, Youyang Zheng, Yan Xiao, Zenglei Zhang, Ge Zhang   +22 more
wiley   +1 more source

Regulatory mechanisms of exercise-induced physiological cardiac hypertrophy: progress and prospects. [PDF]

Front Cardiovasc Med
Cheng P, Zhang X, Si Y, Yin Q, Chen L, Ru Q, Chu C, Xiang H, Liao L, Ran H, Zhang Z, Wu Y.   +11 more
europepmc   +1 more source